Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

hydrocortisone / Generic mfg.

DFCI 16-001, NCT03020030: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Active, not recruiting

560

Canada, US

Pegaspargase, Erwinia asparaginase, ERWINAZE®, ERWINIA CHRYSANTHEMI, ERWINASE®, Cyclophosphamide, CYTOXAN, CYTARABINE, CYTOSINE ARABINOSIDE, ARA-C, CYTOSAR®, DASATINIB, DEXAMETHASONE, DECADRON®, HEXADROL®,, DEXONE®,, DEXAMETH®, Dexrazoxane, Zinecard, Doxorubicin, ADRIAMYCIN®, ETOPOSIDE, VePesid, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, 6-MP, METHOTREXATE, NELARABINE, Vincristine, Oncovin

Dana-Farber Cancer Institute, Servier

Acute Lymphoblastic Leukemia, Pediatric

11/24

11/34

NCT06390319: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Not yet recruiting

145

Dexamethasone, Decadron, Hexadrol®, Vincristine, Vincristine Sulfate, Oncovin, Daunorubicin, Daunomycin, Calaspargase pegol, ASPARLAS, Dasatinib, Sprycel®, Venetoclax, Venclexta®, Bortezomib, Velcade®, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), IT MHA, Cyclophosphamide, Cytoxan®, Cytarabine, Ara-C, Cytosine arabinoside, Mercaptopurine, 6-MP, Nelarabine, Arranon, Atriance, Methotrexate, Trexall®, Thioguanine, 6-thioguanine, Tabloid®

St. Jude Children's Research Hospital, AbbVie

T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia

12/27

12/33

NCT03913559: Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Recruiting

Inotuzumab ozogamicin, Besponsa, CMC-544, Methotrexate, Trexall®, Hydrocortisone, Cortisol, Cytarabine, Ara-C, Diphenhydramine, Benadryl, Acetaminophen, Tylenol, Methylprednisolone, Solu-Medrol

St. Jude Children's Research Hospital, Pfizer

Acute Lymphoblastic Leukemia

12/24

01/25

T2017-002, NCT03817320 / 2019-001947-28: PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Active, not recruiting

1/2

US, RoW

Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin

Therapeutic Advances in Childhood Leukemia Consortium, Takeda, Children's Hospital Los Angeles

ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood

12/24

06/25

NCT05192889: Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Active, not recruiting

1/2

Venetoclax, Venclextra®, ABT-199, Navitoclax, ABT-263, Dexamethasone, Decadron®, Hexadrol®, Dexameth®, Vincristine, Vincristine sulfate, Oncovin®, Calaspargase Pegol, Asparlas, Dasatinib, Sprycel®, Cytarabine, Ara-C, Cytosar-U®, Blinatumomab, Blincyto®, Methotrexate, MTX, Trexall®, amethopterin, Mercaptopurine, 6-MP, Purinethol®, Cyclophosphamide, Cytoxan®, Etoposide, VP-16, Vepesid®, Leucovorin, Folinic acid, Intrathecal Triples, ITMHA, methotrexate/hydrocortisone/cytarabine, Pegaspargase, Oncaspar®, PEG-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Erwinase®, Radiation, Irradiation

St. Jude Children's Research Hospital, AbbVie

Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia

08/25

07/29

NCT04501614 / 2019-002549-39: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Active, not recruiting

1/2

Europe, US, RoW

Ponatinib, Ponatinib AAF, Chemotherapy Agents

Takeda, Takeda Development Center Americas, Inc.

Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)

12/24

01/27

NCT04029688 / 2018-004579-11: A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Active, not recruiting

1/2

Europe, Canada, US

Idasanutlin, RG7388, Venetoclax, RG7601, GDC-0199, ABT-199, Cyclophosphamide, Topotecan, Fludarabine, Cytarabine, Intrathecal Chemotherapy

Hoffmann-La Roche

Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors

06/24

12/25

NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Recruiting

1/2

Europe, Canada, US, RoW

Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide

Daiichi Sankyo, Inc., Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group

Acute Myeloid Leukemia

05/27

SELCLAX, NCT04898894: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Recruiting

Venetoclax, Venclextra®, ABT-199, Selinexor, KPT-330, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar®, Fludarabine, Fludara®, Fludarabine phosphate, 2-fluoro-ara-AMP, Filgrastim, G-CSF, Methotrexate, MTX, amethopterin, Trexall®, methotrexate/hydrocortisone/cytarabine, ITMHA, Intrathecal triples

St. Jude Children's Research Hospital, Karyopharm Therapeutics Inc, AbbVie, Gateway for Cancer Research

Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia

07/23

07/25

NCT06177067: Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Recruiting

Revumenib, SNDX-5613, Venetoclax, Venclextra®, Azacitidine, VIDAZA®, 5-azacitidine, intrathecal (IT) chemotherapy, ITMHA, methotrexate/hydrocortisone/cytarabine, Cytarabine, Ara-C, Cytosar®, Methotrexate, MTX, Trexall®

St. Jude Children's Research Hospital, Syndax Pharmaceuticals

Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage

01/26

07/26

NCT02303821 / 2014-001633-84: Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Active, not recruiting

130

Europe, Canada, US, RoW

Carfilzomib, PR-171, PR171, Kyprolis® (carfilzomib) for Injection, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin

Amgen, Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator, Innovative Therapies For Children with Cancer Consortium

Acute Lymphoblastic Leukemia (ALL)

07/24

NCT05974410: Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Available

N/A

AVM0703, Hydrocortisone, Proton pump inhibitor

AVM Biotechnology Inc

Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Breast Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Acute Leukemia, Pancreatic Cancer, Spindle Cell Sarcoma, Cancer, Tumor, Solid, Tumor, Brain



	Diseases Companies Products Productz Mechanisms of Action Sites